Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2010

View Archived Issues

CD56(bright) NK cell count predicts response to daclizumab in relapsing-remitting MS

Second dose enhances immunogenicity of MenACWY-TT flu vaccine in toddlers

Recent preclinical studies offer insight into mechanism of action of laquinimod

New clinical data presented on anticancer agents GSK-2118436 and GSK-1120212

Intravenous zanamivir administration is feasible in patients with severe flu

Takeda Pharma claims novel renin inhibitors

BMPR-1A inhibition by RAP-661 increases bone mass and strength in mice

Treakisym approved in Japan for non-Hodgkin's and mantle cell lymphoma

Evotec and Apeiron Biologics collaborate on DREAM modulators for pain

Shionogi obtains approval for pediatric use of peramivir in Japan

PTC Therapeutics begins phase II ataluren trial in nmMMA

MacroGenics and Pfizer enter into DART collaboration and license agreement

Achillion Pharmaceuticals patents novel antibacterial agents

Initial phase II results of resminostat in Hodgkin's lymphoma demonstrate favorable safety

New GSK-3 beta inhibitors claimed

Keryx completes enrollment in short-term phase III efficacy study of Zerenex

Cephalon gains TNF inhibitor assets with exercise of option to acquire BioAssets Development

Astellas Pharma's Vesicare OD approved in Japan for overactive bladder

New blockers of voltage-gated Ca(V)2.2 calcium channel described

Purdue Pharma and Mundipharma to develop Infinity Pharma's FAAH program

EpiCept to conduct phase III trial of Ceplene under FDA SPA

Pradax approved in Canada for stroke prevention in AF

Celator Pharma completes enrollment in phase II CPX-351 trial in AML

Nascobal to be commercialized outside U.S. for vitamin B12 deficiency

Pfizer obtains new indication approval for Lyrica in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...